All posts related to "plaque psoriasis"

Call for patient organization input on apremilast for moderate to severe plaque psoriasis

Megaphone GraphicCall for patient organization input on apremilast (Otezla®) for moderate to severe plaque psoriasis

Do you have moderate to severe plaque psoriasis or care for someone who does? If so, we need your valuable input.

The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for apremilast (Otezla®) for the treatment of moderate to severe plaque psoriasis. Apremilast is an oral, small-molecule compound, taken as one tablet twice a day. In phase II and III clinical trials it has been shown to be effective and well tolerated for treating plaque psoriasis. The medication works by inhibiting the action of phosphodiesterase-4 (PDE4). PDE4 is an enzyme found in immune cells.

Continue reading